Oncolytic HSV BiTE Expression for Safer Tumor-Targeted Immunotherapy
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current cancer therapies, particularly immunotherapies using bispecific T-cell engagers (BiTEs), face challenges such as neurotoxicity and cytokine release syndrome due to systemic delivery, necessitating improved therapeutic compositions and methods to ameliorate these issues.
Innovation Solution
The use of recombinant oncolytic viral vectors, like modified herpes simplex viruses, engineered to express immune cell engagers with T-cell binding and tumor-associated antigen binding domains, which are administered to redirect and activate immune cells to target tumor cells, thereby enhancing antitumor activity.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Object-affected harmful factors
If systemic delivery of BiTEs is used, then tumor targeting capability is improved, but neurotoxicity and cytokine release syndrome occur
Solution Approach 1:
The patent uses oncolytic viruses as intermediary carriers to deliver BiTEs selectively to tumor cells. The virus acts as a mediator that transports the therapeutic protein to the target site, avoiding systemic circulation and its associated toxicities. The virus infects tumor cells and expresses BiTEs within the tumor microenvironment, achieving localized tumor targeting without the harmful systemic effects of conventional BiTE administration.
Solution Approach 2:
The invention implements local quality by confining BiTE expression to the tumor site through oncolytic virus infection. Instead of systemic distribution, the BiTEs are produced locally within tumor cells and the tumor microenvironment. This localized production mechanism ensures that the therapeutic activity is concentrated where needed (at the tumor) while avoiding exposure of healthy tissues to the harmful effects of BiTEs.
2Productivity
If oncolytic viruses are used to express immune cell engagers, then tumor targeting and immune activation are enhanced, but virus replication control becomes complex
Solution Approach 1:
The patent segments the viral genome to separate the oncolytic function from the therapeutic payload function. The oncolytic virus provides tumor-specific replication and cell lysis, while the BiTE expression cassette provides the immunostimulatory function. This segmentation allows independent optimization of each function: the virus replicates selectively in tumors to provide oncolysis, while simultaneously producing BiTEs for immune activation, without requiring complex coordination between the two functions.
Solution Approach 2:
The oncolytic virus vector is designed with multi-functionality, simultaneously providing tumor cell lysis, immune activation through BiTE expression, and potential immunomodulation. This universal approach consolidates multiple anti-tumor mechanisms into a single viral platform, achieving enhanced antitumor activity while managing complexity through integrated design rather than separate therapies.
Data Source
AI summary
An HSV vector with an expression cassette encoding an immune cell engager protein under control of an EF1α promoter. ICP27 under control of a CEA promoter. ICP34.5 under control of miRNA-124/143, and ICP47 under control of a ICP27 promoter is disclosed. The HSV vector also includes deletion of one copy of terminal repeat long region and one copy of terminal repeat short region. The immune cell engager protein comprises a T-cell binding domain and a tumor-associated antigen binding domain.